|
Press Releases |
|
 |
|
Monday, August 1, 2016 |
|
Eisai Presents Results of Additional Analysis of Phase III Study of Anticancer Agent Halaven at 14th JSMO Annual Meeting Plenary Session |
Eisai Co., Ltd. announced today that the results of an additional analysis of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven in patients with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). more info >> |
|
Eisai and Mamorio to Jointly Develop "Me-MAMORIO" Tracking Tool to Support People With Dementia Going Out |
Eisai Co., Ltd. and MAMORIO, Inc. announced today that they have entered into an agreement to collaborate on the development of the MeMAMORIO1 tracking tool to support people with dementia going out. more info >> |
|
Friday, July 22, 2016 |
|
Eisai Receives Positive CHMP Opinion on New Indication for Anticancer Agent Lenvatinib in Combination with Everolimus for Treatment of Advanced Renal Cell Carcinoma |
Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent lenvatinib mesylate in combination with everolimus. more info >> |
|
Wednesday, July 20, 2016 |
|
U.S. FDA Approves BELVIQ XR, A Once-Daily Formulation of Lorcaserin for Chronic Weight Management |
Eisai Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for BELVIQ XR, a once-daily formulation of lorcaserin hydrochloride (generic name, U.S. brand name: BELVIQ) for chronic weight management. more info >> |
|
Thursday, June 30, 2016 |
|
Eisai listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible Investment |
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 15th consecutive year since its initial inclusion in 2002. more info >> |
|
Monday, June 20, 2016 |
|
AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease |
AbbVie GK, Eisai Co., Ltd., and its subsidiary EA Pharma Co., Ltd. today announced the additional approval for a new dosing regimen of Humira Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection, a fully human anti-TNF monoclonal antibody formulation, in patients with moderate or severe Crohn's disease who become less responsive to treatment with 40 mg every two weeks to double the dose to 80 mg every two weeks. more info >> |
|
Thursday, June 16, 2016 |
|
Eisai Launches New Oral Suspension Formulation for Antiepileptic Drug Fycompa (Perampanel) in the United States |
Eisai Co., Ltd. announced today that it has launched Fycompa (perampanel) Oral Suspension, a new formulation of its in-house-discovered antiepileptic drug (AED) Fycompa, in the United States. more info >> |
|
Friday, June 3, 2016 |
|
Eisai Inc. Enters Into Collaboration Agreement to Co-Promote Eisai's Anticancer Agent Lenvima in Combination with Evorolimus as Treatment for Advanced Renal Cell Carcinoma in the United States |
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into an agreement with Novartis Pharmaceuticals Corporation, a U.S. affiliate of Novartis AG, to collaborate on commercial and medical affairs activities for Eisai's in-house developed novel anticancer agent Lenvima and the anticancer agent everolimus in the United States. more info >> |
|
Wednesday, June 1, 2016 |
|
AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Field of Gastrointestinal Disease |
AbbVie GK, Eisai Co., Ltd. and its subsidiary EA Pharma Co., Ltd., announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-alpha monoclonal antibody HUMIRA for indications in the field of gastrointestinal disease (ulcerative colitis, Crohn's disease, intestinal Behcet's disease) as of today. more info >> |
|
Wednesday, May 25, 2016 |
|
Eisai to Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) |
Eisai Co., Ltd. announced today that it will launch its in-house-discovered antiepileptic drug (AED) Fycompa Tablets 2 mg and 4 mg (perampanel hydrate) as an adjunctive therapy for partial-onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs in Japan on May 26, 2016. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Kuvi.ai Launches Private Beta of Agentic Finance OS with Seed Round Led by Moon Pursuit Capital
Aug 2, 2025 11:30 HKT/SGT
|
|
|
Rust Mobile Revealed With Official Trailer, First Hands-on Demo Set for Gamescom 2025
Aug 2, 2025 00:30 HKT/SGT
|
|
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
Aug 2, 2025 00:02 HKT/SGT
|
|
|
TSE Group Launches Papua's First POME-to-Energy Plant
Aug 1, 2025 23:00 HKT/SGT
|
|
|
Concord New Energy (0182.HK) Released 2025 Interim Results
Aug 1, 2025 21:49 HKT/SGT
|
|
|
Queensland's Stralis lands clean aviation breakthrough in Japan, announced at Expo 2025 Osaka
Aug 1, 2025 20:00 JST
|
|
|
Queensland leads global education charge at Expo 2025 Osaka
Aug 1, 2025 20:00 JST
|
|
|
Hitachi completes capital reorganization of air conditioning joint venture accelerating the deployment of green cooling solutions through "One Hitachi"
Aug 1, 2025 19:00 JST
|
|
|
Naoris Protocol Stakes $120,000 Bounty To Break Cryptography Securing $470 Trillion Global Economy
Aug 1, 2025 16:50 HKT/SGT
|
|
|
Mitsubishi Motors and Security Bank launch Mitsubishi Motors Finance Philippines Inc.
Aug 1, 2025 17:00 JST
|
|
|
Honda Turkiye A.S. decided to establish Motorcycle Production Factory
Aug 1, 2025 16:45 JST
|
|
|
Global Property Expo | Singapore 2025 attracts 2,500 Buyers With Intent, 40+ Exhibitors, with Projects spanning 20 Countries
Aug 1, 2025 14:48 HKT/SGT
|
|
|
Honda Begins Joint Demonstration of Stationary Fuel Cell Power Station Designed to Utilize By-product Hydrogen and Repurposed Automotive Fuel Cells
Aug 1, 2025 11:20 JST
|
|
|
Isuzu's first battery-electric pickup "D-MAX EV" adopts eAxle
Aug 1, 2025 11:00 JST
|
|
|
A Bold New Chapter Begins at CEO SUITE
Aug 1, 2025 10:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|